In October 2024, a team of Chinese researchers at Peking University reported that a 25-year-old woman who had lived with Type 1 diabetes since childhood stopped needing insulin injections within 75 days of receiving an experimental stem cell transplant ge

The trial’s success has prompted broader clinical exploration, with media outlets highlighting islet cell transplant advancements as a potential paradigm shift in diabetes care. Coverage from *Diabetes In Control* and *KGUN 9* frames the development as a landmark step, though specifics on trial scale or patient outcomes beyond the initial case remain limited. *Space Daily* and *Rockdale Citizen* emphasize the expansion of clinical trials, while *The Spokesman-Review* invites public discussion on accessibility and ethical considerations.

Next steps hinge on trial enrollment growth, regulatory approval timelines, and whether broader patient groups replicate the initial results. Coverage does not yet specify which stem cell methods are being scaled or if the Chinese team is leading the expansion.